Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 2Anatomic Stage IV Breast Cancer AJCC v8 2Lymphoma, Follicular 1Dementia 1Cognitive Dysfunction 1Brain Neoplasms 1Anxiety Disorders 1Anomia 1Anatomic Stage I Breast Cancer AJCC v8 1Alzheimer Disease 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Hormones × 1 year × Clear all
NCT06660862 2026-01-08

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

University of Chicago

Phase 4 Not yet recruiting
80 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03721341 2025-09-18

SABR-COMET 10

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 3 Active not recruiting
204 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡